Heron Therapeutics (HRTX) Research & Development (2010 - 2026)

Heron Therapeutics has reported Research & Development for 17 years, with the latest figure at $2.4 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 4.65% year-over-year to $2.4 million; the trailing twelve-month figure through Mar 2026 stood at $12.5 million (down 12.67% YoY), and the FY2025 full-year result was $12.4 million, down 25.5% from the prior year.
• Research & Development for Q1 2026 stood at $2.4 million, down from $3.7 million in the prior quarter.
• The five-year high for Research & Development was $42.1 million in Q1 2022, with the low at -$13.7 million in Q4 2022.
• Historically, Research & Development has averaged $9.0 million across 5 years, with a median of $4.5 million in 2024.
• Annual changes were most pronounced in 2022 — Research & Development tumbled 147.6% — and 2023, when it soared 156.76%.
• Heron Therapeutics' Research & Development stood at -$13.7 million in 2022, then surged by 156.76% to $7.8 million in 2023, then plunged by 59.27% to $3.2 million in 2024, then grew by 17.87% to $3.7 million in 2025, then slumped by 36.33% to $2.4 million in 2026.
• The last three Research & Development figures came in at $2.4 million (Q1 2026), $3.7 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.